Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Nephrology · Anti-glomerular basement membrane disease

Prognosis and Long-Term Health

At a Glance

After Anti-GBM disease, kidney recovery may take weeks or months and depends on kidney function at diagnosis and biopsy damage. If recovery does not occur, dialysis and transplant remain options; transplant is usually considered after remission and at least six months of undetectable antibodies.

The journey following an Anti-GBM diagnosis is often divided into two phases: the acute “storm” of intensive treatment and the long-term management of your health. While the initial goal is to save your life and preserve organ function, the long-term focus shifts to stabilizing your kidney function, managing any chronic damage, and monitoring for signs of relapse [1][2].

Predicting Kidney Recovery

One of the most profound questions after diagnosis is whether the kidneys will regain their ability to filter blood. It is important to know that recovery can sometimes take weeks or months; therefore, End-Stage Kidney Disease (ESKD) is not usually declared immediately after presentation, even if you temporarily need acute dialysis [3]. Your medical team will look at several factors to estimate your prognosis:

  • Dialysis Status at Presentation: Studies indicate that patients who do not require dialysis when they are first diagnosed have a much higher likelihood of preserving long-term kidney function [3]. For patients who arrive at the hospital already requiring dialysis, the chance of recovering enough function to stop dialysis is lower, though certainly not impossible [3][4].
  • Biopsy Findings: The amount of permanent damage seen on your biopsy provides critical clues. A higher proportion of “normal” (unaffected) glomeruli is associated with better chances of recovery [3][5]. Conversely, if nearly 100% of the filters show severe “crescents” or if there is extensive chronic scarring (Interstitial Fibrosis/Tubular Atrophy or IFTA), the likelihood of regaining independent kidney function is very low [5][6].
  • No single percentage or rule guarantees a specific outcome. Your nephrologist will interpret these observational findings in the context of your unique case.

Life After the Acute Phase

If your kidneys do not recover, you will transition to long-term End-Stage Kidney Disease (ESKD) management, which involves chronic hemodialysis or peritoneal dialysis.

Regardless of your kidney function, monitoring for a return of the disease (relapse) is a key part of long-term care:

  • For classic Anti-GBM disease, relapse is uncommon. While new symptoms should always be evaluated promptly, routine maintenance immunosuppression is generally not required once the initial disease is fully treated [7][8].
  • If you are double-positive (testing positive for both anti-GBM and ANCA antibodies), your risk of relapse is notably higher. Your long-term care will follow protocols for ANCA-associated vasculitis, which may include years of “maintenance” medication and closer monitoring of your urine and blood [9][7].

Looking Toward Kidney Transplant

For patients whose kidneys have been permanently scarred, a kidney transplant offers an excellent long-term solution. Patients with Anti-GBM disease tend to have very successful transplant outcomes, with survival rates comparable to those who receive transplants for other conditions [10][11].

The Transplant Timeline

You cannot safely receive a new kidney while the disease is still active. Most transplant centers follow these guidelines:

  1. Clinical Remission: Your overall health must be stable, and the initial autoimmune attack must be completely resolved, with infections well controlled [12].
  2. Undetectable Antibodies: Generally, you must wait until the anti-GBM antibodies have been permanently undetectable in your blood for at least six months [12][13].

The risk of Anti-GBM disease attacking a new transplanted kidney is generally estimated to be very low (less than 2% in some observational cohorts), especially when strict waiting periods for antibody clearance are observed [14].

Long-Term Health Priorities

Whether you are recovering kidney function, managing dialysis, or preparing for a transplant, your long-term health plan requires a collaborative approach with your team:

  • Blood Pressure and Fluid Management: Follow the specific, individualized blood pressure targets and fluid intake limits set by your nephrology team to ensure adequate blood flow without overloading your system.
  • Routine Lab Work: Regular urinalysis (checking for blood or protein) and blood tests (monitoring creatinine and eGFR) are essential to catch any early signs of kidney strain or rare relapses [15]. Note that some blood or protein in the urine can persist simply from the prior injury, which is why your doctor monitors the trends.
  • Medication Management: Work with your team on a safe schedule for tapering steroids, protecting your bone and stomach health, and maintaining your dialysis access points.

While the diagnosis of Anti-GBM disease is life-altering and intense, many patients successfully navigate the acute crisis and find stability through specialized care, vigilant monitoring, and the possibility of a transplant [10][2].

Common questions in this guide

Can my kidneys recover after I start dialysis for Anti-GBM disease?
Yes, recovery is sometimes possible, and it may take weeks or months; needing acute dialysis does not automatically mean that kidney failure is permanent. The chance is generally lower when dialysis was already needed at diagnosis and when a biopsy shows extensive damage. Your nephrologist will reassess your kidney function and response to treatment over time.
What biopsy findings affect kidney recovery in Anti-GBM disease?
A higher number of unaffected kidney filters is linked with a better chance of recovering independent kidney function. Extensive scarring or severe crescent-shaped injury in nearly all of the filters is linked with a very low chance of recovery. These findings estimate prognosis but cannot predict one person’s outcome with certainty.
Does double-positive Anti-GBM and ANCA disease have a higher relapse risk?
Yes. People who test positive for both anti-GBM and ANCA antibodies have a higher relapse risk than people with classic Anti-GBM disease. They may need closer urine and blood monitoring and longer-term maintenance immune-suppressing medicine, as advised by their specialist.
When can I have a kidney transplant after Anti-GBM disease?
A transplant is considered only after the autoimmune attack is in clinical remission, overall health is stable, and infections are controlled. Most centers also wait until anti-GBM antibodies have remained undetectable for at least six months. Once these conditions are met, transplant outcomes are generally very good and recurrence in the new kidney is uncommon.
What follow-up care is needed after the acute phase of Anti-GBM disease?
Follow-up commonly includes individualized blood pressure and fluid goals, urine tests for blood or protein, and blood tests such as creatinine and eGFR. Your team may also monitor antibodies, adjust or taper steroids safely, protect bone and stomach health, and check dialysis access when applicable. Persistent blood or protein in the urine can reflect earlier injury, so trends over time are important.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy and response to treatment, what is your assessment of my likelihood of coming off dialysis, recognizing that this can evolve over time?
  2. 2.Am I considered 'double-positive' for both anti-GBM and ANCA antibodies, and how will that specifically change my monitoring over the next few years?
  3. 3.What specific individualized target should we aim for regarding my blood pressure and fluid intake?
  4. 4.If my kidneys do not recover, what is this hospital’s specific protocol and timeline for referring me to a transplant center?
  5. 5.How often will we test my blood for antibodies now that the initial intensive treatment is over, and what other labs (like urine protein) will we watch?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients.

    Liu Y, Wu Y, Wei W, et al.

    Renal failure 2024; (46(2)):2400539 doi:10.1080/0886022X.2024.2400539.

    PMID: 39258391
  2. 2

    Anti-glomerular basement membrane disease: A contemporary case series from a large university hospital center.

    Catarina Oliveira A, Figueiredo R, Correia R, et al.

    Nefrologia 2026; (46(7)):501522 doi:10.1016/j.nefroe.2026.501522.

    PMID: 42618193
  3. 3

    Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.

    Floyd L, Bate S, Hadi Kafagi A, et al.

    Journal of the American Society of Nephrology : JASN 2023; (34(3)):505-514 doi:10.1681/ASN.2022050581.

    PMID: 36446430
  4. 4

    Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort.

    Alchi B, Griffiths M, Sivalingam M, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2015; (30(5)):814-21 doi:10.1093/ndt/gfu399.

    PMID: 25609740
  5. 5

    Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

    van Daalen EE, Jennette JC, McAdoo SP, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2018; (13(1)):63-72 doi:10.2215/CJN.04290417.

    PMID: 29162595
  6. 6

    Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life.

    Sánchez-Agesta M, Rabasco C, Soler MJ, et al.

    Frontiers in medicine 2022; (9()):889185 doi:10.3389/fmed.2022.889185.

    PMID: 35865174
  7. 7

    Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

    McAdoo SP, Tanna A, Hrušková Z, et al.

    Kidney international 2017; (92(3)):693-702 doi:10.1016/j.kint.2017.03.014.

    PMID: 28506760
  8. 8

    Anti-glomerular basement membrane disease-treatment standard.

    McAdoo SP, Pusey CD

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (41(1)):42-54 doi:10.1093/ndt/gfaf190.

    PMID: 40973182
  9. 9

    Recurrent Nephritis and/or Pulmonary Hemorrhage in Patients with Anti-Glomerular Basement Membrane Disease with and without ANCA Positivity.

    Droz N, Katz A, Patel A, et al.

    Glomerular diseases 2021; (1(2)):60-67 doi:10.1159/000515388.

    PMID: 36751425
  10. 10

    Outcomes After Kidney Transplantation in Antiglomerular Basement Membrane Disease.

    Traversat P, Dekervel M, Masset C, et al.

    Kidney international reports 2025; (10(9)):3150-3163 doi:10.1016/j.ekir.2025.06.021.

    PMID: 40980652
  11. 11

    Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease.

    Singh T, Kharadjian TB, Astor BC, Panzer SE

    Clinical transplantation 2021; (35(2)):e14179 doi:10.1111/ctr.14179.

    PMID: 33259076
  12. 12

    Recurrence of Goodpasture syndrome without circulating anti-glomerular basement membrane antibodies after kidney transplant, a case report.

    Thibaud V, Rioux-Leclercq N, Vigneau C, Morice S

    BMC nephrology 2019; (20(1)):6 doi:10.1186/s12882-018-1197-6.

    PMID: 30621605
  13. 13

    Kidney Transplantation After Rituximab Treatment for End-Stage Renal Failure With Myeloperoxidase Anti-neutrophil Cytoplasmic and Anti-glomerular Basement Membrane Antibody Positivity: A Case Report.

    Sugiura T, Tanaka A, Nishibori N, et al.

    Cureus 2025; (17(10)):e94237 doi:10.7759/cureus.94237.

    PMID: 41209892
  14. 14

    Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.

    Coche S, Sprangers B, Van Laecke S, et al.

    Kidney international reports 2021; (6(7)):1888-1894 doi:10.1016/j.ekir.2021.04.011.

    PMID: 34307983
  15. 15

    Late post-transplant recurrence of an anti-myeloperoxydase antibody-associated vasculitis in a former double-positive patient: a case report.

    Chenaf-Benabdelmoumene N, Chabannes M, Ducloux D, et al.

    Frontiers in immunology 2026; (17()):1723903 doi:10.3389/fimmu.2026.1723903.

    PMID: 41716381

This page explains prognosis and long-term care after Anti-GBM disease for informational purposes only and does not replace medical advice. Your nephrologist and transplant team can interpret your results and plan care.

Get notified when new evidence is published on anti-basement membrane glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.